Hematology (all articles)
Editorial: Convalescent plasma for Covid-19
20 Sep, 2020 | 21:29h | UTCConvalescent plasma for covid-19 – The BMJ
Commentary on Twitter
Last month the US FDA authorised the emergency use of convalescent plasma for hospital patients with covid-19. What evidence underpinned the FDA’s controversial decision? And will the authorisation make it more difficult to recruit participants for RCTS? https://t.co/PMO13J2IOq
— The BMJ (@bmj_latest) September 19, 2020
The pooled prevalence of pulmonary embolism in patients with COVID-19
18 Sep, 2020 | 09:37h | UTCThe pooled prevalence of pulmonary embolism in patients with COVID-19 – Intensive Care Medicine
Commentary on Twitter
Pulmonary embolism in #COVID19, be careful! quantitative meta-analysis ->
pooled prevalence in pts undergoing #PE diagnosis 28%
higher pooled prevalence in pts admitted to #ICU vs those admitted to non-ICU: 19 vs 9%
Open access @yourICM #COVIDFOAM #FOAMcc https://t.co/dUqKAVoeCV pic.twitter.com/fvmQnTlv1M— Intens Care Med (@yourICM) September 15, 2020
Investigating whether blood type is linked to COVID-19 risk
17 Sep, 2020 | 09:26h | UTCInvestigating Whether Blood Type Is Linked to COVID-19 Risk – JAMA
Commentary on Twitter
Researchers find no relationship between blood type and severe #COVID19, despite early studies suggesting possible higher risk for those with type A. “The basic science on this is extremely weak.” https://t.co/tYreg896DK
— JAMA (@JAMA_current) September 17, 2020
Multisystem effects of COVID-19: A concise review for practitioners
16 Sep, 2020 | 09:14h | UTCMultisystem effects of COVID-19: A concise review for practitioners – Postgraduate Medicine
Preliminary randomized trial evaluated recombinant human granulocyte colony–stimulating factor for patients with COVID-19 and lymphopenia
11 Sep, 2020 | 01:36h | UTCInvited Commentary: Immune Stimulation With Recombinant Human Granulocyte Colony–Stimulating Factor for Coronavirus Disease 2019 (COVID-19)—Beware of Blind Spots
Commentary on Twitter
Preliminary findings from a randomized clinical trial suggest that rhG-CSF treatment should be studied in larger trials and in a broader range of patients with #COVID19 https://t.co/SjsoWOkEXg
— JAMA Internal Medicine (@JAMAInternalMed) September 10, 2020
Clinical outcomes in young adults hospitalized with COVID-19
10 Sep, 2020 | 09:49h | UTCClinical Outcomes in Young US Adults Hospitalized With COVID-19 – JAMA Internal Medicine
Editorial: Regardless of Age, Obesity and Hypertension Increase Risks With COVID-19
Commentary: Obesity greatest risk factor for young adults with COVID-19 – MedicalXpress
Commentary on Twitter
18 to 34 years old #COVID19 hospitalized outcomes:
✔️21% intensive care,
✔️10% mechanical ventilation
✔️2.7% died.
✔️Morbid obesity, hypertension & diabetes associated with⬆️risks of adverse events.
✔️+ ½ requiring hospitalization: Black or Hispanic⚓️https://t.co/kcs2cery7s pic.twitter.com/ASVB943Bhc
— Medtor #COVID19 (@Medtorek) September 9, 2020
[Preprint] Randomized trial: Convalescent plasma not associated with improved outcomes in Covid-19
9 Sep, 2020 | 09:41h | UTC
Commentary on Twitter
Convalescent Plasma Randomized Controlled Trial (PLACID Trial) in the Management of Moderate #COVID19 (pre-print)
? “not associated with reduction in mortality or progression to severe COVID-19”
Link: https://t.co/2ZXnfemsas@GermHunterMD @MackayIM @CT_Bergstrom #IDTwitter pic.twitter.com/yZuOxVhbjL
— Alvin (@alvie_barr) September 8, 2020
COVID-19 is, in the end, an endothelial disease
8 Sep, 2020 | 01:11h | UTCCOVID-19 is, in the end, an endothelial disease – European Heart Journal
Commentary on Twitter
COVID as an infectious disease of the “endothelium”, the lining of blood vessels, transmitted pre-sympyomatically. Explains the sepsis syndrome; explains the clotting/bleeding; explains the kidney failure.
What a nasty, nasty disease.https://t.co/5hlfL5Iik9
— David Fisman (@DFisman) September 7, 2020
Cohort study: COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumor subtype and patient demographics
6 Sep, 2020 | 21:42h | UTCCommentaries: New study describes which cancer patients are more vulnerable to COVID-19 – University of Birmingham AND COVID-19 Prevalence and Mortality in Patients With Cancer in the UK – The ASCO Post
Systematic review: Association between D-Dimer levels and mortality in patients with COVID-19
6 Sep, 2020 | 21:37h | UTC
Randomized trial: Preoperative intravenous iron to treat anemia 10–42 days before major abdominal surgery does not reduce the need for blood transfusion
6 Sep, 2020 | 21:28h | UTC
Commentary on Twitter
Startling finding. In a blinded RCT, preop iron transfusion did not ⬇️complications, or a ⬇️transfusions after major abdominal surgery. While Hb ⬆️, no real tangible benefit occurred.
Periop medicine & optimization is complicated! #colorectalsurgery https://t.co/q0HhR3JCy3— Ahmer Karimuddin (@ahmerkarimuddin) September 5, 2020
Review: Coagulopathy of Covid-19
4 Sep, 2020 | 02:14h | UTCCoagulopathy of Coronavirus Disease 2019 – Critical Care Medicine
Commentary on Twitter
What you need to know about #Covid19 #coagulopathy is all in one place – @CCM. This will help target your anticoagulation plans for COVID care. @SCCM https://t.co/gKUbc995ra
— Lewis J. Kaplan (@SCCMPresident) September 1, 2020
[Abstract Only] CAR T-cell therapy for patients with relapsed or refractory large B-cell lymphomas
3 Sep, 2020 | 10:56h | UTCLisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study – The Lancet (link to abstract – $ for full-text)
#ESCCongress – [Not Published Yet] Randomized trial on transfusion thresholds in anemic heart attack patients
2 Sep, 2020 | 09:42h | UTCNews Release: Trial clarifies use of blood transfusion in anaemic heart attack patients – European Society of Cardiology
Position Paper: Diagnosis and treatment of pulmonary embolism during the COVID-19 pandemic
1 Sep, 2020 | 06:27h | UTC
Anticoagulation in COVID-19: A systematic review, meta-analysis and rapid guidance from the Mayo Clinic
1 Sep, 2020 | 06:26h | UTC
AGA Guidelines on the gastrointestinal evaluation of iron deficiency anemia
1 Sep, 2020 | 06:02h | UTC
[Abstract Only] Observational study: Therapeutic and prophylactic anticoagulation linked to lower in-hospital mortality in patients with Covid-19
27 Aug, 2020 | 09:51h | UTCCommentaries: Study provides more data on blood thinner efficacy for COVID-19 – The Mount Sinai Hospital AND Anticoagulants Associated With Better Survival, Lower Risk of Intubation in COVID-19 Patients
FDA issues emergency use authorization for convalescent plasma as potential COVID–19 treatment
25 Aug, 2020 | 03:58h | UTCCommentaries: Convalescent Plasma: The Science and the Politics – Science Translational Medicine AND Convalescent plasma: another controversial clash of politics & science – Health News Review AND Observational Study of Convalescent Plasma and FDA Response – datamethods AND FDA OKs use of convalescent plasma for COVID-1 – CIDRAP AND Is convalescent plasma safe and effective? We answer the major questions about the Covid-19 treatment – STAT
Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19
25 Aug, 2020 | 03:53h | UTC
Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients
25 Aug, 2020 | 03:45h | UTC
Study suggests low risk of post-discharge venous thromboembolism following hospital admission with COVID-19
16 Aug, 2020 | 22:24h | UTCPost-discharge venous thromboembolism following hospital admission with COVID-19 – Blood
Commentary: Post-Hospital Venous Thromboembolism in Patients With COVID-19 – American College of Cardiology
Coagulopathy in COVID-19: Manifestations and management
14 Aug, 2020 | 01:21h | UTCCoagulopathy in COVID-19: Manifestations and management – Cleveland Clinic Journal of Medicine
[Preprint] Observational study: Effect of convalescent plasma on mortality among hospitalized patients with COVID-19
14 Aug, 2020 | 01:24h | UTCCommentary: Large study suggests convalescent plasma can help treat Covid-19, but experts have doubts – STAT
Commentary on Twitter
? Preliminary results from convalescent plasma Expanded Access Program ?
35,322 patients ?
Not an RCT ?
But, lower mortality with earlier administration & higher antibody titre support possible efficacy ?https://t.co/xwzz3mQ0qX pic.twitter.com/Utquky4wW1
— Ilan Schwartz MD PhD (@GermHunterMD) August 13, 2020
Systematic review: The use of erythropoietin plus iron to correct anemia before surgery to reduce the risk of blood transfusion
14 Aug, 2020 | 01:04h | UTC